Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results

WASHINGTON, Feb. 12, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the fourth quarter and full year ended December 31, 2012.

Key Highlights:

Vanda reported positive SET and RESET Phase III efficacy studies for tasimelteon in the treatment of patients with Non-24-Hour Disorder (Non-24). Study results demonstrate tasimelteon is a unique circadian regulator that resets the master body clock and improves clinical symptoms in patients with Non-24.
The tasimelteon Non-24 program continues towards the goal of a projected mid-2013 New Drug Application (NDA) filing with the U.S. Food and Drug Administration (FDA).
All tasimelteon activities have been discontinued related to the Major Depressive Disorder (MDD) indication. In January 2013, Vanda announced that the MAGELLAN Phase IIb/III clinical study did not meet its primary endpoint.
Vanda has formally requested a re-examination of the negative opinion issued by the European Medicines Agency (EMA) recommending against approval of Fanaptum™ (oral iloperidone tablets) in the European Union.
Vanda recorded full year 2012 revenue of $32.7 million including Fanapt® royalties of $5.9 million. Fanapt® prescriptions, as reported by IMS, were approximately 38,200 for the fourth quarter of 2012. This represents a 1% decrease versus third quarter 2012 prescriptions and a 13% increase over fourth quarter 2011 prescriptions.

FULL YEAR 2012 REPORTED RESULTS

Total revenues for the full year 2012 were $32.7 million, compared to $31.3 million for 2011. Full year 2012 revenues included $5.9 million in Fanapt^® royalties received from Novartis, as compared to $4.5 million for the prior year. Both 2012 and 2011 revenues include $26.8 million recognized from the $200.0 million upfront payment previously received from Novartis for Fanapt^® U.S. and Canadian rights.

Total operating expenses for 2012 were $61.0 million, compared to $42.0 million for 2011. The primary driver of the higher expenses in 2012 was the ongoing support of the tasimelteon Non-24 and MDD clinical studies.

Vanda recorded a net loss of $27.7 million for 2012, compared to net loss of $9.8 million for 2011. Diluted net loss per share for 2012 was $0.98, compared to a diluted net loss per share of $0.35 for 2011.

Vanda's cash, cash equivalents and marketable securities as of December 31, 2012 totaled $120.4 million.

FOURTH QUARTER 2012 REPORTED RESULTS

Total revenues for the fourth quarter of 2012 were $7.9 million, compared to $8.4 million for 2011. Fourth quarter 2012 revenues included $1.2 million in Fanapt^® royalties received from Novartis as compared to royalties of $1.6 million for the fourth quarter of 2011.

Total operating expenses for the fourth quarter of 2012 and 2011 were each $14.3 million.

Vanda recorded a net loss of $6.4 million for the fourth quarter of 2012, compared to a net loss of $5.5 million for the fourth quarter of 2011. Diluted net loss per share for the fourth quarter of 2012 was $0.23, compared to a diluted net loss of $0.20 per share for the fourth quarter of 2011.

Full Year December 31, 2012 Key Financial Figures¹

	Twelve Months Ended
	December 31	December 31
(in thousands, except per share amounts)	2012	2011	Change ($)	Change (%)

Total revenues	$ 32,727	$ 31,270	$ 1,457	5%
Research & development expenses	45,446	28,996	16,450	57%
General & administrative expenses	13,882	11,486	2,396	21%
Non-cash stock-based compensation²	4,094	5,501	(1,407)	(26%)
Loss before tax benefit	(27,664)	(10,246)	(17,418)	(170%)
Tax benefit	-	(444)	444	100%
Net loss	(27,664)	(9,802)	(17,862)	(182%)

Diluted net loss per share	$ (0.98)	$ (0.35)	$ (0.63)	(180%)

Fourth Quarter 2012 Key Financial Figures¹

	Three Months Ended
	December 31	September 30
(in thousands, except per share amounts)	2012	2012	Change ($)	Change (%)

Total revenues	$ 7,920	$ 8,288	$ (368)	(4%)
Research & development expenses	10,617	10,159	458	5%
General & administrative expenses	3,225	3,147	78	2%
Non-cash stock-based compensation²	923	576	347	60%
Loss before tax benefit	(6,369)	(5,326)	(1,043)	(20%)
Tax benefit	-	-	-
Net loss	(6,369)	(5,326)	(1,043)	(20%)

Diluted net loss per share	$ (0.23)	$ (0.19)	$ (0.04)	(21%)

Select Cash Flow Data¹

	Twelve Months Ended
	December 31	December 31
(in thousands)	2012	2011
Net cash provided by (used in)
Operating activities	$ (44,917)	$ (28,410)
Investing activities	45,754	73,749
Financing activities	12	25

Select Balance Sheet Data¹

	December 31	September 30	December 31
(in thousands)	2012	2012	2011

Total cash and marketable securities	$ 120,403	$ 134,404	$ 167,896

(1) Unaudited

(2) Non-cash stock-based compensation is allocated to both Research & development and General & administrative expenses

OPERATIONAL HIGHLIGHTS

In December 2012 and January 2013, Vanda announced positive results for two Phase III studies for tasimelteon in the treatment of Non-24. The SET Phase III study demonstrated that tasimelteon was able to entrain the master body clock as measured by melatonin and cortisol circadian rhythms. Tasimelteon was also shown to significantly improve clinical symptoms across a number of sleep and wake measures. These results provided robust evidence of direct and clinically meaningful benefits to patients with Non-24. The RESET Phase III study demonstrated the maintenance effect of 20mg of tasimelteon to entrain melatonin and cortisol circadian rhythms in individuals with Non-24. Patients treated with tasimelteon maintained their clinical benefits while patients receiving placebo showed significant deterioration in measures of nighttime sleep, daytime naps and timing of sleep. Non-24 is a serious, rare circadian rhythm disorder that affects a majority of totally blind individuals who lack light perception and cannot entrain (reset) their master body clock to the 24-hour day. Currently there is no approved treatment for Non-24.

Vanda plans to submit an NDA to the FDA in mid-2013. Vanda will meet with the FDA in Q1 of 2013 for a pre-NDA meeting on tasimelteon in the treatment of patients with Non-24.

Vanda has decided to discontinue all activities related to the MDD indication. In January, Vanda announced that the MAGELLAN Phase IIb/III clinical study in MDD did not meet the primary endpoint of a change from baseline in the Hamilton Depression Scale (HAMD-17) after 8 weeks of treatment as compared to placebo.

Vanda has formally appealed the EMA's negative opinion for Fanaptum™ (oral iloperidone tablets) and requested a re-examination of the decision by the EMA's Committee for Medicinal Product for Human Use (CHMP). In December 2012, the CHMP issued a negative opinion recommending against approval of Fanaptum™ for the treatment of schizophrenia in adult patients in the European Union.

Vanda recorded full year 2012 revenue of $32.7 million including Fanapt^® royalties of $5.9 million. Fanapt^® prescriptions, as reported by IMS, were approximately 38,200 for the fourth quarter of 2012. This represents a 1% decrease versus third quarter 2012 prescriptions and a 13% increase over fourth quarter 2011 prescriptions.

CONFERENCE CALL

Vanda has scheduled a conference call for today, Tuesday, February 12, 2013, at 10:00 AM ET. During the call, Vanda's management will discuss the fourth quarter and full year 2012 results and other corporate activities. Investors can call 800-901-5248 (domestic) and 617-786-4512 (international) and use passcode 86594010. A replay of the call will be available beginning Tuesday, February 12, 2013 at 12:00 PM ET and will be accessible until Tuesday, February 19, 2013, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 89804635.

The conference call will be broadcast simultaneously on Vanda's website, http://www.vandapharma.com. Investors should click on the Investor Relations tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations. The call will also be archived on Vanda's website for a period of 30 days, through March 14, 2013.

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. For more on Vanda, please visit http://www.vandapharma.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "project," "target," "goal," "likely," "will," "would," and "could," or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: the inability to reach agreement with the FDA regarding Vanda's regulatory approval strategy or proposed path to approval for tasimelteon for the treatment of Non-24; Vanda's failure to obtain regulatory approval for tasimelteon for the treatment of Non-24 or to comply with ongoing regulatory requirements; the extent and effectiveness of the development, sales and marketing and distribution support Fanapt^® receives; Vanda's ability to successfully commercialize Fanapt^® outside of the U.S. and Canada and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2011 which is on file with the SEC and available on the SEC's website at www.sec.gov. In addition to the risks described above and in Vanda's annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.



	VANDA PHARMACEUTICALS INC.
	CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)


			Three Months Ended				Twelve Months Ended
(in thousands, except for share)			December 31		December 31		December 31		December 31
and per share amounts)			2012		2011		2012		2011

Revenues:
	Licensing agreement		$	6,752	$	6,752	$	26,789	$	26,789
	Royalty revenue			1,168		1,618		5,938		4,481
		Total revenues		7,920		8,370		32,727		31,270

Operating expenses:
	Cost of sales			129		-		129		-
	Research and development			10,617		10,556		45,446		28,996
	General and administrative			3,225		3,345		13,882		11,486
	Intangible asset amortization			377		377		1,495		1,495
		Total operating expenses		14,348		14,278		60,952		41,977

Loss from operations				(6,428)		(5,908)		(28,225)		(10,707)
	Other income			59		99		561		461
Loss before tax benefit				(6,369)		(5,809)		(27,664)		(10,246)

	Tax benefit			-		(286)		-		(444)

Net loss			$	(6,369)	$	(5,523)	$	(27,664)	$	(9,802)

Net loss per share:
	Basic		$	(0.23)	$	(0.20)	$	(0.98)	$	(0.35)
	Diluted		$	(0.23)	$	(0.20)	$	(0.98)	$	(0.35)

Shares used in calculation of net loss
	per share:
	Basic			28,233,409		28,115,175		28,228,409		28,106,831
	Diluted			28,233,409		28,115,175		28,228,409		28,106,831



VANDA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)


(in thousands)				December 31, 2012		December 31, 2011

ASSETS
	Current assets:
		Cash and cash equivalents		$	88,772	$	87,923
		Marketable securities, current			31,631		60,961
		Accounts receivable			1,168		1,618
		Inventory			57		-
		Prepaid expenses and other current assets			3,910		2,999
		Restricted cash, current			430		-
			Total current assets		125,968		153,501

	Marketable securities, non-current				-		19,012
	Property and equipment, net				2,348		964
	Other assets, non-current				-		84
	Intangible asset, net				6,532		8,027
	Restricted cash, non-current				600		1,030
			Total assets	$	135,448	$	182,618


LIABILITIES AND STOCKHOLDERS' EQUITY
	Current liabilities:
		Accounts payable		$	287	$	996
		Accrued liabilities			5,187		3,381
		Deferred rent, current			-		453
		Deferred revenues, current			26,789		26,789
			Total current liabilities		32,263		31,619

	Non-current liabilities:
		Deferred rent, non-current			3,005		461
		Deferred revenues, non-current			90,275		117,064
			Total liabilities		125,543		149,144

	Stockholders' equity:
		Common stock			28		28
		Additional paid-in capital			300,974		296,868
		Accumulated other comprehensive income			10		21
		Accumulated deficit			(291,107)		(263,443)
			Total stockholders' equity		9,905		33,474

			Total liabilities and stockholders' equity	$	135,448	$	182,618